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Abstract: Platinum complexes derived from two families of bidentate funcionalized aroylaminocarbo-N-thyoyl prolinates are prepared using 
mild conditions from prolinates, which are available via 1,3-dipolar cycloadditions. The resulting four coordinated neutral square-planar 
platinum(II) complexes are very stable and are fully characterized. Their structures are determined by spectroscopic and analytical methods 
and one of them by single crystal X-ray diffraction analysis. In this pattern, the platinum exhibits distorted square planar geometry, with cis-bond 
angles ranging from 89.42(2) and 94.37(6)° and trans-bond angles of 176.19(6) and 177.08(6)°, respectively.  Anti(myco)bacterial and antifungal 
studies of all these new compounds are carried out under standardized protocols. 
 
Introduction 
Apart from catalytic activity, platinum complexes exhibit important 
pharmacological and biological properties and attract the 
attention of many synthetic organic chemists. They are very 
important complexes in the medicinal chemistry area mainly 
displaying remarkable antitumor activity [1]. However, many other 
complexes showed antimicrobial, antiviral [2a] antileishmanial, 
and antitubercular [2b] activities. The modification of the nature of 
the ligand, anchored to the metal centre, can expand the 
interaction with microorganisms. For example, this effect is shown 
for some platinum(II) complexes bearing thiourea-type ligands, 
which possess interesting biological properties such as 
anticancer [3], antibacterial/antifungal [4,5,6], antimalarial [7] and 
antituberculosis [8] activities. Besides, the presence of a 
pyrrolidine ring is crucial due to the synergistic effects observed 
in the bioactivity of many compounds [9] and also this heterocycle 
was the core structure for the construction of biologically 
important entities [10].  
With all these details in mind, we envisaged that the fusion 
of pyrrolidine and -C(O)NHC(S)- functional moieties into a 
platinum complex would be an attractive framework to study. In 
this context, our group has previously reported the synthesis of 
polysubstituted aroylaminocarbo-N-thioyl pyrrolidines and their 
Ni(II), Pd(II) and Cu(II) complexes [11]. Also, the presence of the 
(3-indolyl)methyl group attached to the quaternary carbon (C2 of 
the pyrrolidine ring) is an important aspect to survey. It was 
reported that this substituent was a key structural element for the 
stability of the final rearranged family of succinimides, increasing 
the biological activity of them [12a].   
Here we will detail the synthesis of novel square-planar 
platinum(II)-complexes of cyclic and bicyclic highly functionalized 
aroylaminocarbo-N-thioyl prolinates from condensation of 
pyrrolidines with isothiocyanates. The biological activities of 
prepared compounds against M. tuberculosis H37Rv strain and 
Staphylococcus aureus (ATCC 25925), Bacillus subtilis (ATCC 
6633), Escherichia coli (ATCC 25923), Acinetobacter baumannii 
(ATCC 02026), and Aeromonas hydrophila (ATCC 95080) 
standard strains and the anti-fungal activities against Candida 
albicans ATCC 14053, C. tropicalis ATCC 1369 and C. glabrata 
ATCC 15126 yeast strains are evaluated too. 
Results and Discussion 
Continuing with our research focussed on the structure activity 
relationship (SAR) of heterocyclic compounds and their metal 
complexes as bioactive agents, we know that molecules 1, which 
were obtained from 1,3-dipolar cycloaddition reaction between 
the α-amino ester and the maleimide via imine-azomethine ylide 
in toluene or xylene [12] in 73-95% yields, resulted to be very 
attractive since the biological and chemical point of view [10]. In 
fact, their potential utility of them as bioactive agents has been 
demonstrated [10]. The bicyclic highly functionalized 
aroylaminocarbo-N-thioyl prolinate ligands 2a-e were next 
synthesized by the condensation of phenyl isothiocyanate and the 
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corresponding fused pyrrolidine 1 under refluxing acetonitrile for 
48 h (Scheme 1) [10a]. Immediately, the square-planar 
platinum(II) complexes 3a-e were prepared form molecules 2 (in 
60-75% yield)  by reaction with K2PtCl2 in acetonitrile-H2O at room 
temperature for 48-72 h and recrystallized from DCM-MeOH as 
indicated in Scheme 1. The complexes 3a-e were characterized 
using NMR, IR, microanalyses, mass spectrometry (MALDI-Tof), 
and HRMS experiments. Despite of their potential crystalline 
structure none of them gave satisfactory crystals to be analysed 




Scheme 1. Synthetic route for the preparation of platinum(II) complexes 3. 
 
 
Looking for an appropriate crystalline structure, prolinate 
derivatives incorporating other different groups at carbon atom 
number 4 were prepared. It is also known that this structural 
arrangement showed alternative activity against microorganisms 
[12,13]. In this sense, a new family of series of compounds 4, 5 
and 6 were designed. Starting compounds endo-prolinates 4, 
were generated by 1,3-DC of the corresponding imino esters and 
methyl acrylate in 70-89% yields  [12]. They were allowed to react 
with phenyl isothiocyanate in refluxing acetonitrile to obtain 
compounds 5a-c in good yields.  Following the reaction conditions 
of the Scheme 1 the synthesis of platinum(II) complexes 6 was 
successfully achieved in 69-85% yield (Scheme 2).   
 
 
Scheme 2. Synthetic route for the preparation of platinum(II) complexes 6. 
 
Fortunately, the structure of 6a was confirmed by a single 
crystal X-ray diffraction studies (Figure 1) [14]. Inspection of the 
crystallographic data confirmed that the platinum(II) complex 6a 
was neutral square-planar molecule using the thioureido 
group/moiety as an efficient stabilizing bidentate ligand. In 
addition, crystal structural analysis of 6a corresponded to a meso-
compound, which is in agreement with the results reported in a 
previous work [11]. The data of crystal structure of 6a, 
[C31H31N2O7S]2Pt are depicted in Figure. 1, crystallographic data 
with selected atomic distances and bond angles are listed in Table 
1-3, and refined by a full matrix least squares technique based on 
F2 using SHELXL2014. 
The compound 6a crystallised as yellow blocks in the P 1 
space group with one molecule in the asymmetric unit. The 
molecular structure is shown in Figure 1. The bond lengths for 
Pt(1)–S(1) = 2.2184(7) Å , Pt(1)–O(1) = 2.0117(18) Å, Pt(1)–S(2) 
= 2.2346(7) Å and Pt(1)–O(8) =2.0260(18) Å and the angles 
between S(1)-Pt(1)-S(2) = 89.42(2), O(1)–Pt(1)–S(1) = 94.37(6), 
O(1)–Pt(1)–S(2) = 176.19(6), O(1)–Pt(1)–O(8) = 84.00(7), O(8)–
Pt(1)–S(1) = 177.08(6) and O(8)–Pt(1)–S(2) = 92.24(5). The 
platinum exhibits the already mentioned distorted square planar 
geometry, with cis bond angles ranging from 89.42(2) and 
94.37(6)° and trans bond angles of 176.19(6) and 177.08(6)° 
(Table 2 and 3). Minor disorder was observed around one of the 
phenyl rings, which was modelled in a 60:40 ratio, with thermal 
ellipsoids restrained using a rigid bond restraint. There is no 
evidence of hydrogen bonding or π-π interactions in the solid 
state.  
 
Table 1: Crystallographic data for 6a. 
Empirical formula  C62H62N4O14PtS2  
Formula weight  1346.36  
Temperature/K  121(1)  
Crystal system  triclinic  
Space group  P-1  
a/Å  14.3323(2)  
b/Å  14.3931(2)  
c/Å  15.4532(2)  
α/°  91.1570(10)  
β/°  105.0220(10)  






Volume/Å3  3077.90(7)  
Z  2  
ρcalcg/cm
3  1.453  
μ/mm-1  2.414  
F(000)  1368.0  
Crystal size/mm3  0.16 × 0.11 × 0.06  
Radiation  Mo Kα (λ = 0.71073)  
2Θ range for data 
collection/°  
6.092 to 62.266  
Index ranges  -20 ≤ h ≤ 20, -20 ≤ k ≤ 20, -21 
 ≤ l ≤ 22  
Reflections collected  54186  
Independent reflections  17532 [Rint = 0.0403, Rsigma = 
 0.0505]  
Data/restraints/parameters  17532/63/774  
Goodness-of-fit on F2  1.039  
Final R indexes [I>=2σ (I)]  R1 = 0.0358, wR2 = 0.0668  
Final R indexes [all data]  R1 = 0.0509, wR2 = 0.0728  
Largest diff. peak/hole / e Å-3  1.57/-0.78  
 
Table 2: Selected bond lengths for 6a. 
Atom Atom Length/Å 
Pt1 S1 2.2184(7) 
Pt1 O1 2.0117(18) 
Pt1 S2 2.2346(7) 
Pt1 O8 2.0260(18) 
 
Table 3: Selected bond angles for 6a. 
Atom Atom Atom Angle/˚ 
S1 Pt1 S2 89.42(2) 
O1 Pt1 S1 94.37(6) 
O1 Pt1 S2 176.19(6) 
O1 Pt1 O8 84.00(7) 
O8 Pt1 S1 177.08(6) 






Figure 1.  Crystal structure corresponding to compound 6a [14]. 
 
 
Antibacterial activity. Stock solutions were prepared by 
dissolving the tested compounds in DMSO and then diluting in 
Mueller-Hinton broth and the test medium were prepared at 
concentrations of 500, 250, 125, 62.5, 31.25, 15.62, 7.8, 3.9 and 
1.9 µg/mL. The minimum inhibitory concentrations (MIC)  values 
was determined by broth dilution in duplicate as recommended by 
the Clinical Laboratory Standards Institute [15].  To ensure that the 
solvents had no effect on microbial growth, a control test was 
performed containing inoculated broth supplemented with DMSO 
which used for the test compounds 1a, 2a, 3a-e and 6a-c. The 
MIC values of the compounds were investigated against standard 
bacterial strains, obtained from the Refik Saydam Hıfzısıhha 
Institute, Ankara, Turkey. The antibacterial activity were assessed 
against two Gram (+) bacteria Staphylococcus aureus (ATCC 
25925), Bacillus subtilis (ATCC 6633) and three Gram (–) bacteria 
Escherichia coli (ATCC 25923), Acinetobacter baumannii (ATCC 
02026), and Aeromonas hydrophila (ATCC 95080). The MIC  
values for the compounds (1a and 2a)  were found in the range of 
15,62 – 125 µg/ml and for the platinium complexes (3a-e) and (6a-
c)  in the range of 31,25 – 500 µg/mL. The control, ampicillin, 
showed activity with a range of 0.9-31.25 µg/mL against the 
tested bacteria as given in Table 1. The ligand molecule 2a 
revealed the highest activities with the MIC values of 15.62 µg/mL 
when tested against Aeromonas hydrophila (ATCC 95080). 
Anti-tuberculosis (TB) activity. Anti-TB activity of the tested 
compounds was performed according to literature method 
utilizing Microplate Alamar Blue assay [16]. The anti-tuberculosis 
activity of the novel target compounds (1a, 2a, 3a-3e, 6a-6c) were 
tested against M. tuberculosis H37Rv strain and measured by 
means of  the minimum inhibitory concentrations (MIC) values 
(µg/mL). Thus Streptomycin (Sigma S6501), Izoniazid (INH) 
(Sigma I3377), Rifampicin (Sigma R3501), Ethambutol (EMB) 
(Sigma E4630) were used as standard known active reference 
drugs (Table 1). The bioactivity of the target compounds showed 
activity, in the range of 7.81-62.5 µg/mL (Table 2). The ligand 
molecule 2a bearing phenyl, 4-chlorophenyl and methyl ester 
moieties revealed the highest activities with the MIC values of 
7.81 µg/mL whereas the rest of molecules 1a, 3a-3e, 6a-c showed 
moderate anti-TB activities in 62.5 µg/mL MIC values against M. 
tuberculosis H37Rv strain. Although biological target/ the mode of 
action of these novel molecules is unknown at the moment it 
seems that some molecules needs further alteration to increase 
their activity by modification of some part of the structure. 
 
Anti-fungal activity. The anti-fungal activities of the target 
compounds (1a, 2a, 3a-3e, 6a-6c) were tested against Candida 
albicans ATCC 14053, C. tropicalis ATCC 1369 and C. glabrata 
ATCC 15126 yeast strains according to the NCCLS standard 
document M27-A2 [17] using the microdilution broth procedure 
[18,19]  and measured by means of MIC values (µg/mL). Candida 
strains were obtained from Refik Saydam Hıfzıssıhha Institute, 
Ankara, Turkey. Antifungal activities were performed in RPMI 
1640 Medium (Sigma, R6504) which buffered to pH 7.0 with 0.165 
M 3-(N-morpholino)-propanesulfonic acid (MOPS, Sigma, 
M1254) as outlined in document. Stock solutions of the tested 
compounds and reference antifungal agent were prepared in 
DMSO at a concentration of 1000 μg/mL. Standard strains is 
diluted by a 1:100 dilution followed by a 1:20 dilution of the stock 
suspension with RPMI 1640 medium which were then filtered via 
a 0.22 μm membrane. The fluconazole (Sigma, F8929) was used 
as standard known active reference drug and  showed activity 
with a range of 3.90-31.25 µg/ml when tested against the 
indicated yeast. The novel tested molecules (1a, 2a, 3a-3e, 6a-c) 
showed moderate anti-fungal activities in the range of 125-250  
























1a 62,5 µg/mL 62,5 µg/mL 31,25 µg/mL 125 µg/mL 31,25 µg/mL 62,5 µg/mL 
2a 62,5 µg/mL 62,5 µg/mL 31,25 µg/mL 125 µg/mL 15,62 µg/mL 7.81 µg/mL 
3a 62,5 µg/mL 62,5 µg/mL 31,25µg/mL 125 µg/mL 31,25 µg/mL 62,5 µg/mL 
3b 250 µg/mL 250 µg/mL 125 µg/mL 250 µg/mL 500 µg/mL 62,5 µg/mL 
3c 62,5 µg/mL 62,5 µg/mL 31,25 µg/mL 125 µg/mL 31,25 µg/mL 62,5 µg/mL 
3d 500 µg/mL 250 µg/mL 125 µg/mL 250 µg/mL 62,5 µg/mL 62,5 µg/mL 
3e 250 µg/mL 250 µg/mL 125 µg/mL 62,5 µg/mL 62,5 µg/mL 62,5 µg/mL 
6a 250 µg/mL 250 µg/mL 125 µg/mL 250 µg/mL 500 µg/mL 62,5 µg/mL 
6b 62,5 µg/mL 62,5 µg/mL 31,25 µg/mL 125 µg/mL 31,25 µg/mL 62,5 µg/mL 
6c 250 µg/mL 250 µg/mL 125 µg/mL 250µg/mL 125 µg/mL 62,5 µg/mL 
Ampicillin 32.25 15.62 125 0.9 31.25  
Streptomycin      0,06 µg/mL 
Izoniazid      0,12 µg/mL 
Rifampicin      0,97 µg/mL 
Etambutol      1,95 µg/mL 
 
 










1a 125 µg/mL 125 µg/mL 125 µg/mL 
2a 125 µg/mL 250 µg/mL 125 µg/mL 
3a 250 µg/mL 125 µg/mL 250 µg/mL 
3b 125 µg/mL 125 µg/mL 125 µg/mL 
3c 250 µg/mL 250 µg/mL 125 µg/mL 
3d 125 µg/mL 125 µg/mL 250 µg/mL 
3e 250 µg/mL 250 µg/mL 125 µg/mL 
6a 125 µg/mL 125 µg/mL 125 µg/mL 
6b 125 µg/mL 125 µg/mL 125 µg/mL 
6c 125 µg/mL 125 µg/mL 250 µg/mL 




The N-benzoylthiourea framework possessing pharmacophores 
containing prolinate units resulted to be a very strong bidentate 
ligand towards the platinum atom affording very stable planar 
dimeric entities. These series of highly pure complexes were 
isolated in good yields. Antibacterial, antituberculosis, and 
antifungal studies of all these new compounds revealed that 
molecule 2a possesed the highest activity with the MIC values of 
15.62 µg/mL when tested against Aeromonas hydrophila. This 
level is much more effective than the own shown by Ampicillin. In 
addition, the same molecule 2a exhibited the highest activities 
with the MIC values of 7.81 µg/mL against M. tuberculosis H37Rv 
strain. All families of derivatives were tested as antigungals 
showing moderate activities in the range of 125-250  µg/mL MIC 
values, which are very high with respect to the effective 
fluconazole doses. At the moment, the biological properties and 
the mode of action for corresponding molecules is unknown, but 
we are currently modifying some substituents of the skeleton in 
order to increase their activities text of the article should appear 
here with headings as appropriate. 
Experimental Section 
General procedure for the synthesis of aminocarbothiolpyrrolidines 
(2 and 5): To a solution of the corresponding pyrrolidine (1.2 mmol) in dry 
acetonitrile (25 mL) was added dropwise benzoyl isothiocyanate (0.213 
mL, 1.3 mmol) in dry acetonitrile (15 mL). The resulting solution was stirred 
at room temperature for 24-48 h or reflux 48 h. After completion of the 
reaction by monitoring TLC, the solvent removed and purified by flash 
chromatography. 
General procedure for the synthesis of platinium complexes (3a-e, 
6a-c): In a flask containing the corresponding aminocarbothiolpyrrolidine 
(2 mmol) in acetonitrile (20 mL), K2PtCl4 (1mmol) in water (10 mL) was 
added and the resulting solution was stirred at room temperature 48-72 h 
or under reflux for 24-48 h. The solvent was evaporated and the crude 
mixture was analysed by 1H NMR and then crystallised in appropriate 
solvent to give a yellow solid. 
X-Ray Crystallographic Analysis of 6a: Measurements were carried out 
at 120K on an Agilent SuperNova diffractometer equipped with an Atlas 
CCD detector and connected to an Oxford Cryostream low temperature 
device using mirror monochromated /Mo K  radiation ( = 0.7107 Å) from 
a Microfocus X-ray source. The structure was solved by intrinsic phasing 
using SHELXT [20] and refined by a full matrix least squares technique 
based on F2 using SHELXL2014 [21]. 
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